BridgeBio Pharma
BBIO
BBIO
210 hedge funds and large institutions have $6.56B invested in BridgeBio Pharma in 2021 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 83 increasing their positions, 61 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
2.04% less ownership
Funds ownership: 95.52% → 93.48% (-2%)
22% less call options, than puts
Call options by funds: $19.6M | Put options by funds: $25M
22% less capital invested
Capital invested by funds: $8.46B → $6.56B (-$1.9B)
Holders
210
Holding in Top 10
15
Calls
$19.6M
Puts
$25M
Top Buyers
| 1 | +$30M | |
| 2 | +$26.7M | |
| 3 | +$20.2M | |
| 4 |
Charles Schwab
San Francisco,
California
|
+$15M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.1M |
Top Sellers
| 1 | -$88.8M | |
| 2 | -$59.9M | |
| 3 | -$43.4M | |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$41M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$23.4M |